Christian Kollmannsberger

Author

Also Known As

C K Kollmannsberger, C Kollmannsberger, C. K. Kollmannsberger, C. Kollmannsberger, C.K. Kollmannsberger, CHRISTIAN KOLLMANNSBERGER, Christian K. Kollmannsberger, Christian K Kollmannsberger, Christian K. Kollmannsberger, Christian Kollmannsberger

717

Publications

38K

Citations

H-Index

136

Concepts

All Affiliations

BC Cancer Agency Dana-Farber Cancer Institute Princess Margaret Cancer Centre University of Calgary University of British Columbia

About

Christian Kollmannsberger is an author at BC Cancer Agency specializing in medicine, oncology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	47	125	10.5K
2	Health Sciences	20	26	2.2K
3	Public Health	5	5	271
4	Arts	1	1	23
5	Engineering	1	1	151

Christian Kollmannsberger

233

Publications

34K

Citations

H-Index

Page 1

	Year	Citations
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma Robert J. Motzer, Bernard Escudier, Saby George, New England Journal of Medicine	2015	5.8K
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma Robert J. Motzer, Nizar M. Tannir, Osvaldo Arén Frontera, New England Journal of Medicine	2018	4.5K
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma Robert J. Motzer, Konstantin Penkov, John B.A.G. Haanen, New England Journal of Medicine	2019	2.5K
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan, Journal of Clinical Oncology	2009	2.1K
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan, The Lancet Oncology External ValidationUrologyPopulation-based StudyGenitourinary CancerMedicine	2013	1K
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial Robert J. Motzer, Brian I. Rini, David F. McDermott, The Lancet Oncology UrologyGenitourinary CancerMedicinePharmacologyImmune Checkpoint Inhibitor	2019	763
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial Laurence Albigès, Nizar M. Tannir, Mauricio Burotto, ESMO Open	2020	515
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer Matti Annala, Gillian Vandekerkhove, Daniel Khalaf, Cancer Discovery PathologyRapid ResistanceInvasive BiomarkersTumor BiologyGenitourinary Cancer	2018	507
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study Hans J. Hammers, Elizabeth R. Plimack, Jeffrey R. Infante, Journal of Clinical Oncology Tyrosine Kinase InhibitorUrologyOncologyGenitourinary CancerMedicine	2017	502
Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium Daniel Y.C. Heng, J. Connor Wells, Brian I. Rini, European Urology UrologySurgical OncologyGenitourinary CancerMedicineCytoreductive Nephrectomy	2014	467

Page 1